Global Antibody Partnering Terms and Agreements Directory 2014-2020: Q4 Updated Details of Deals by the World’s Leading Healthcare Companies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–Feb 4, 2021–
The "Global Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com’s offering.
The Global Antibody Partnering Terms and Agreements 2014 to 2020 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,600 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.
Key benefits
Global Antibody Partnering Terms and Agreements 2014 to 2020 provides the reader with the following key benefits:

  • In-depth understanding of Antibody deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Antibody agreements with real life case studies
  • Detailed access to actual Antibody contracts enter into by the leading twenty five bigpharma companies
  • Insight into the terms included in a Antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in antibody dealmaking
2.1. Introduction
2.2. Antibody partnering over the years
2.3. Most active antibody dealmakers
2.4. Antibody partnering by deal type
2.5. Antibody partnering by therapy area
2.6. Deal terms for antibody partnering
2.6.1 Antibody partnering headline values
2.6.2 Antibody deal upfront payments
2.6.3 Antibody deal milestone payments
2.6.4 Antibody royalty rates
Chapter 3 – Leading antibody deals
3.1. Introduction
3.2. Top antibody deals by value
Chapter 4 – Most active antibody dealmakers
4.1. Introduction
4.2. Most active antibody dealmakers
4.3. Most active antibody partnering company profiles
Chapter 5 – Antibody contracts dealmaking directory
5.1. Introduction
5.2. Antibody contracts dealmaking directory
Chapter 6 – Antibody dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices

  • Appendix 1 – Antibody deals by company A-Z
  • Appendix 2 – Antibody deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 – Antibody deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Appendix 4 – Antibody deals by therapy area
  • Cardiovascular
  • Central Nervous System
  • Dental
  • Dermatology
  • Gastrointestinal
  • Hematology
  • Hospital care
  • Immunology
  • Infectives
  • Metabolic
  • Musculoskeletal
  • Obstetrics
  • Oncology
  • Ophthalmics
  • Orphan disease
  • Pediatrics
  • Psychiatry
  • Respiratory
  • Appendix 5 -Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/6wi4nw
View source version on businesswire.com:https://www.businesswire.com/news/home/20210204005482/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/04/2021 03:51 AM/DISC: 02/04/2021 03:51 AM
http://www.businesswire.com/news/home/20210204005482/en